TAIPEI, TAIWAN – With the official opening in Taiwan of its new preclinical and early clinical quantity biopharmaceutical plant last week, another milestone has been reached in rapid fashion by the upstart JHL Biotech Co. Ltd.
TAIPEI, Taiwan – With a number of novel biologics looking good in late-stage multisite FDA- or EMA-authorized clinical trials, Taiwan’s biopharmaceutical sector is starting to fulfill its early promise, rewarding the faith of its backers – both government and private sector – after decades of slow progress. Local production capacity is now ramping up; at least seven companies have their own manufacturing facilities and more are on the way.
TAIPEI, Taiwan – Astrazeneca plc and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) are collaborating to repurpose a basket of clinical-stage drug candidates provided by the London-based big pharma for possible new therapies targeting Asian-prevalent diseases, using an open innovation model of development.
TAIPEI, Taiwan – Astrazeneca plc and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) are collaborating to repurpose a basket of clinical-stage drug candidates provided by the London-based big pharma for possible new therapies targeting Asian-prevalent diseases, using an open innovation model of development.
TAIPEI, Taiwan – Drug reformulation specialist Taiwan Liposome Co. (TLC), of Taipei, Taiwan, said it granted Sciclone Pharmaceuticals Inc., of Foster City, Calif., exclusive rights to distribute Proflow, its treatment for peripheral arterial disease (PAD), in China, Macau and Hong Kong.
TAIPEI, Taiwan – Drug reformulation specialist Taiwan Liposome Co. (TLC), of Taipei, Taiwan, said it granted Sciclone Pharmaceuticals Inc., of Foster City, Calif., exclusive rights to distribute Proflow, its treatment for peripheral arterial disease (PAD), in China, Macau and Hong Kong.
TAIPEI, Taiwan – Diminutive drug discovery firm PRISM Pharma Co. Ltd., of Yokohama, Japan, has closed a Series C round of funding of approximately ¥1.4 billion (US$15 million) with the funds earmarked for upcoming clinical trials for the company's investigative oncology drug PRI-724 in non-oncology related conditions, initially fibrosis.
TAIPEI, Taiwan – It's been a long wait, but Taiwan's drug development industry might just be coming of age. While the island nation is still awaiting its first home-grown innovator drug, a number of companies are almost there.
TAIPEI, Taiwan – It's been a long wait, but Taiwan's drug development industry might just be coming of age. While the island nation is still awaiting its first home-grown innovator drug, a number of companies are almost there.
TAIPEI, Taiwan – In what is likely one of the first attempts by a foreign biopharma to complete the full range of clinical trials in China for a new biologic, leading to regulatory and market approval by Chinese drug approval authorities, therapeutic antibodies specialist RuiYi Inc., of La Jolla, Calif., and Shanghai, entered a collaboration agreement with Genor BioPharma Co. Ltd., of Shanghai, to develop its anti-IL-6 monoclonal antibody RYI-008 for rheumatoid arthritis (RA).
